Cell Therapeutics (CTIC) Il mio nome è Therapeutic! ...Cell therapeutic !.....2° atto
- Creatore Discussione patt
- Data di Inizio
-
- Tags
- cell therapeutic
patt
Forumer storico
Re: una volta tanto
sembrerebbe una buoan notizia...e aggiungo che l'appoggio dell'FDA a velocizzare gli studi....risuona come un gesto di fiducia a riguardo della societa' stessa.......
ora occorrerebbe qualche istituzionale che cominciasse a comperare come si deve....e pulisse il book dai soliti 4 monovratori......del...beeeeeep........che portanoa spasso le quotazioni...
i volumi si sono visti.......oltre i 22.000.000 da noi...
felixeco ha scritto:una news che non è la solita bufala
sembrerebbe una buoan notizia...e aggiungo che l'appoggio dell'FDA a velocizzare gli studi....risuona come un gesto di fiducia a riguardo della societa' stessa.......
ora occorrerebbe qualche istituzionale che cominciasse a comperare come si deve....e pulisse il book dai soliti 4 monovratori......del...beeeeeep........che portanoa spasso le quotazioni...
i volumi si sono visti.......oltre i 22.000.000 da noi...
patt
Forumer storico
Cell Therapeutics, Inc. Announces $37.2 Million Offering
Thursday April 12, 7:00 am ET
SEATTLE, April 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has entered into agreements to sell approximately $37.2 million of its 3% Convertible Preferred Stock and warrants in a registered offering to several institutional investors, including existing securities holders. CTI will sell Series B convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of Series B convertible preferred stock. The Preferred Stock will be convertible into shares of common stock beginning on April 16, 2007, at a conversion price of $1.6825 per share ($6.73 per share following the one-for-four reverse stock split effective on April 15). Purchasers will also receive warrants to purchase common stock in an amount equal to 50% of their total investment amount divided by $1.6825 ($6.73 post-split), which warrants will have an exercise price of $1.62 per share ($6.48 post-split), which is equal to the closing bid price of the Company's common stock as reported on the Nasdaq Global Market on April 10, 2007. The warrants will not be exercisable until six months following the closing.
ADVERTISEMENT
The offering is expected to close on April 16, 2007, subject to certain closing conditions.
Rodman & Renshaw, LLC acted as the exclusive placement agent for the offering.
A shelf registration statement relating to the preferred stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our Convertible Preferred Stock or warrants. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
DOR rejects buyout offer
Thursday April 12, 4:43 pm ET
DOR BioPharma said its board has rejected a buyout offer from Cell Therapeutics as being "inadequate for shareholders."
The Miami-based biotech got an unsolicited bid from Cell Therapeutics in January. The Seattle-based company offered to issue DOR (OTCBB: DORB - News) shareholders 29 million shares of Cell Therapeutics (NASDAQ: CTCI - News) common stock.
ADVERTISEMENT
The company also said it would pay $15 million if the Food and Drug Administration approves DOR's new drug application for orBec. That drug is a treatment for gastrointestinal graft-versus-host disease and could be approved this year. DOR's next FDA hearing is set for May 9.
DOR said it deliberated the potential Cell Therapeutics deal with a committee of independent board members before unanimously deciding against it.
The company still has one more offer on the table.
In January, it signed a letter of intent for Sigma-Tau Pharmaceuticals, part of Italy-based Sigma-Tau Group, to negotiate for a deal involving orBec acquisition or licensing. Sigma-Tau bought $1 million DOR shares at 25 cents each and paid $2 million in cash for the right to negotiate.
DOR shares closed up 3 cents to 65 cents. The 52-week high was 71 cents on Feb. 21. The 52-week low was 20 cents on Aug. 21.
Published April 12, 2007 by the South Florida Business Journal
Thursday April 12, 7:00 am ET
SEATTLE, April 12 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTAX) today announced that it has entered into agreements to sell approximately $37.2 million of its 3% Convertible Preferred Stock and warrants in a registered offering to several institutional investors, including existing securities holders. CTI will sell Series B convertible preferred stock and warrants to investors at the negotiated price of $1,000 per share of Series B convertible preferred stock. The Preferred Stock will be convertible into shares of common stock beginning on April 16, 2007, at a conversion price of $1.6825 per share ($6.73 per share following the one-for-four reverse stock split effective on April 15). Purchasers will also receive warrants to purchase common stock in an amount equal to 50% of their total investment amount divided by $1.6825 ($6.73 post-split), which warrants will have an exercise price of $1.62 per share ($6.48 post-split), which is equal to the closing bid price of the Company's common stock as reported on the Nasdaq Global Market on April 10, 2007. The warrants will not be exercisable until six months following the closing.
ADVERTISEMENT
The offering is expected to close on April 16, 2007, subject to certain closing conditions.
Rodman & Renshaw, LLC acted as the exclusive placement agent for the offering.
A shelf registration statement relating to the preferred stock and warrants to be issued in the offering has been filed with the Securities and Exchange Commission and has become effective. A prospectus supplement related to the offering will be filed with the Securities and Exchange Commission. Copies of the prospectus supplement and accompanying base prospectus may be obtained directly from Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This announcement is neither an offer to sell nor a solicitation of an offer to buy any of our Convertible Preferred Stock or warrants. No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful.
This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. The risks and uncertainties include the risk that the above described transaction will not close as a result of the failure to meet closing conditions, investors may breach or withdraw their commitment, and until closed there is no assurance that it will close or what the total amount may be, and other risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.
DOR rejects buyout offer
Thursday April 12, 4:43 pm ET
DOR BioPharma said its board has rejected a buyout offer from Cell Therapeutics as being "inadequate for shareholders."
The Miami-based biotech got an unsolicited bid from Cell Therapeutics in January. The Seattle-based company offered to issue DOR (OTCBB: DORB - News) shareholders 29 million shares of Cell Therapeutics (NASDAQ: CTCI - News) common stock.
ADVERTISEMENT
The company also said it would pay $15 million if the Food and Drug Administration approves DOR's new drug application for orBec. That drug is a treatment for gastrointestinal graft-versus-host disease and could be approved this year. DOR's next FDA hearing is set for May 9.
DOR said it deliberated the potential Cell Therapeutics deal with a committee of independent board members before unanimously deciding against it.
The company still has one more offer on the table.
In January, it signed a letter of intent for Sigma-Tau Pharmaceuticals, part of Italy-based Sigma-Tau Group, to negotiate for a deal involving orBec acquisition or licensing. Sigma-Tau bought $1 million DOR shares at 25 cents each and paid $2 million in cash for the right to negotiate.
DOR shares closed up 3 cents to 65 cents. The 52-week high was 71 cents on Feb. 21. The 52-week low was 20 cents on Aug. 21.
Published April 12, 2007 by the South Florida Business Journal
informazioni su collocamento azioni privilegiate
Salve,volevo avere delle informazioni in merito al collocamento di azioni privilegiate e warrant,con successva possibilità,dal 16 Aprile,di convertirle in azioni ordinarie,dato che ho in portafoglio un piccolo quantitativo di titoli da qualche giorno.I dubbi principali riguardano:
-Possibili perdite e/o guadagni;-Possibilità nella conversione immediata senza avere alcun vincolo;-A quale prezzo verrano convertite;-Qualche consiglio di come mi devo comportare;
Aspetto vostri suggerimenti e nel frattempo vi ringrazio per la disponibilità.
Salve,volevo avere delle informazioni in merito al collocamento di azioni privilegiate e warrant,con successva possibilità,dal 16 Aprile,di convertirle in azioni ordinarie,dato che ho in portafoglio un piccolo quantitativo di titoli da qualche giorno.I dubbi principali riguardano:
-Possibili perdite e/o guadagni;-Possibilità nella conversione immediata senza avere alcun vincolo;-A quale prezzo verrano convertite;-Qualche consiglio di come mi devo comportare;
Aspetto vostri suggerimenti e nel frattempo vi ringrazio per la disponibilità.
patt
Forumer storico
Re: informazioni su collocamento azioni privilegiate
al momento non posso riportarti nulla che possa esserti utile....se trovassi qualcosa te lo posto.
vi ricordo che oggi....
Cell Therapeutics. Raggruppamento azionario in rapporto di una nuova azione ogni 4 vecchi titoli
preopen a 4,7€ ...prezzo di controllo...4,68€
davidgekko ha scritto:
al momento non posso riportarti nulla che possa esserti utile....se trovassi qualcosa te lo posto.
vi ricordo che oggi....
Cell Therapeutics. Raggruppamento azionario in rapporto di una nuova azione ogni 4 vecchi titoli
preopen a 4,7€ ...prezzo di controllo...4,68€
Re: informazioni su collocamento azioni privilegiate
ok grazie.patatino ha scritto:
patt
Forumer storico
http://www.cticseattle.com/investors_news.htm
oggi i dati...... la partenza c'è stata......visti i precedenti.......meglio attendere....
oggi i dati...... la partenza c'è stata......visti i precedenti.......meglio attendere....